FDA: 2021 NEW DRUG THERAPY APPROVALS IN ONCOLOGY

2021 marked the 50th anniversary of the National Cancer Act, landmark legislation committed to fighting cancer. In this anniversary year, FDA’s Center for Drug Evaluation and Research (CDER) approved many therapies for different cancers. Four new drugs were approved for non-small cell lung cancer, including one non-small cell lung cancer type previously thought to be resistant to treatment. CDER also approved therapy for some types of basal cell carcinoma, the most common form of skin cancer, for certain patient ...

Далее...


ASCO WILL SUPPORT RAKFOND CLINICAL TRIAL WORKSHOP FOR YOUNG INVESTIGATORS

The American Society of Clinical Oncology (ASCO) is partnering with RakFond on the “Clinical Trial Workshop for Young Investigators,” which will be held on February 2-4, 2022, in Moscow, Russia. ASCO will assist in the program development and provide faculty for the joint session. The event also has been included in the ASCO event calendar. The call for proposals is now open to young investigators who would like to participate in the workshop. More details, terms, and application forms are available at the event web page: https://www.rakfond.org/школа/. We ...

Далее...


PRESENT AND FUTURE OF ONCOLOGY

This year, our long-term partner and donor, the Russian Society of Clinical Oncology (RUSSCO), is celebrating a double anniversary – 10 years of the society and 25 years of the Oncology Congress and RosOncoWeb. It is a great honor for us to work together on projects in advancing cancer research, and on behalf of the RakFond team, we congratulate our colleagues, send our gratitude for supporting our initiatives, and wish them many years of prosperity and success!   At the XXV Russian Oncology Congress, RakFond and RUSSCO held a joint session supported by Con...

Далее...


RESULTS OF THE COMPETITION OF RESEARCH PROJECTS IN ONCOLOGY

The review of the applications for the Competition of research projects in oncology (RFP 2021-01) has been completed. Overall, 17 full applications were received, 14 of them passed the formal compliance check and were sent for a scientific review. The maximum weighted score in this competition was 33. The rating of the applications based on the results of the scientific review is presented below. Detailed information on the winner and the project is posted on our website in the Supported Research section. 2021-01-08 30.5...

Далее...


XXV RUSSIAN ONCOLOGY CONGRESS

Joint Session of RUSSCO and RakFond with Consilium Scientific PRESENT AND FUTURE OF ONCOLOGY Chairs: Dr. Nikolay Zhukov, D. Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow> Prof. Tatiana Semiglazova, N.N. Petrov National Medical Research Center for Oncology, Saint Petersburg   08:50-09:00 – Introduction Dr. Nikolay Zhukov, D. Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology, Moscow 09:00-09:10 - Introduction Prof. ...

Далее...


ANNUAL CANCER PROGRESS REPORT ISSUED BY THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

отчет AACR РакФонд
DISCOVERY SCIENCE DRIVING CLINICAL BREAKTHROUGHS The American Association for Cancer Research (AACR) released its annual Cancer Progress Report, which highlights advances over the past 12 months in the prevention, detection, diagnosis, and treatment of cancer. Below is a brief summary of this report. CANCER IN 2021 • According to the latest estimates from World Health Organization (WHO), cancer was the first or second leading cause of death before the age of 70 in 112 out of 183 countries in 2019 and accounted for nearly 10 million deaths worldwide in 2020. • ...

Далее...


The Nobel Prize in Physiology or Medicine in 2021 was awarded for the discovery of receptors for temperature and touch

David Julius and Ardem Patapoutian were awarded the Nobel Prize in Physiology or Medicine in 2021. Their discoveries were focused on TRP-ion channels, the receptors responsible for heat and cold, and PIEZO-ion channels, the receptors for touch, which are also involved in sensing body position. The signal activation of ion channels that will subsequently be perceived by the brain makes these receptors vital for our survival. The study of ion channels, "sensors" of physiological state, helps to better understand the mechanisms responsible for pain, the transmission of ...

Далее...


THE RESULTS OF CHRONOS19 STUDY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND COVID-19 IN RUSSIA WERE PRESENTED AT 2021 ESMO ANNUAL MEETING

This year's meeting of the European Society for Medical Oncology (ESMO) took place online on September 16-21. In frames of the scientific program, a poster on the treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies was presented by CHRONOS19 investigators. A full abstract can be found here: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/treatment-outcomes-and-antibody-immunity-to-sars-cov-2-in-patients-with-hematological-malignancies

Далее...


ASCO’s Clinical Cancer Advances 2021 Report

ASCO’s Clinical Cancer Advances annual report highlights current trends in the field and identifies cancer research priorities that have great potential to advance progress against cancer. The 16th edition of the annual report was developed by a 26-member editorial board of experts. The editors reviewed scientific literature published in peer-reviewed journals or presented at major medical conferences, primarily from October 2019 to September 2020, selected advances that improve meaningful patient outcomes and have a strong scientific impact, and proposed priority areas ...

Далее...


CHRONOS19 WILL BE PRESENTED AT THE EHA 2021 VIRTUAL CONGRESS

The results of the subgroup analysis of the CHRONOS19 registry in patients with acute leukemia and COVID-19 will be presented orally by the study PI Olga Gavrilina, MD, PhD, at the upcoming in June annual congress of the European Hematology Association (EHA) during the special session on the SARS-CoV-2 infection “COVID-19 impact on hematology: How it started - How it’s going”. Patients with acute leukemia are at high risk of COVID-19 severe and lethal course. Intensive chemotherapy and immunosuppression in these patients are the possible causes of high ...

Далее...